Pantoprazole Crescent Pharma (Pantoprazole)

Pantoprazole Crescent Pharma is a proton pump inhibitor that acts on gastric acid secretion pathways. It is indicated for:

• Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and promotes healing of erosive esophagitis.
• Erosive esophagitis: heals damage to the esophageal lining caused by acid exposure.
• Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with gastrin‑secreting tumors.
• Peptic ulcer disease prevention: reduces recurrence of duodenal and gastric ulcers when used with NSAIDs or after ulcer healing.

• Pantoprazole selectively inhibits the H+/K+‑ATPase enzyme (the gastric proton pump) located on the secretory surface of parietal cells. By binding covalently to the pump in its active state, it blocks the final step of acid secretion, leading to a sustained increase in gastric pH and reduced acidity in the stomach.

Pantoprazole may cause a range of adverse reactions. Most are mild and reversible, but rare events can be serious.

Common Side Effects

• Headache: mild to moderate intensity.
• Diarrhoea: loose stools, usually transient.
• Nausea: occasional feeling of queasiness.
• Abdominal pain: cramp‑like discomfort.
• Flatulence: increased intestinal gas.
• Constipation: reduced bowel movements.

Serious or Rare Side Effects

• Clostridioides difficile infection: severe colitis presenting with watery diarrhoea.
• Acute interstitial nephritis: kidney inflammation with reduced urine output.
• Hypomagnesemia: low serum magnesium causing muscle cramps or arrhythmia.
• Stevens‑Johnson syndrome/toxic epidermal necrolysis: severe skin reactions.
• Hepatic dysfunction: elevated liver enzymes or jaundice.
• Bone fracture risk: increased incidence of hip, wrist or vertebral fractures with long‑term use.

When prescribing Pantoprazole Crescent Pharma, clinicians should consider several safety aspects.

• Assess renal function: dose adjustment may be needed in severe impairment.
• Review concomitant medications: potential for drug‑drug interactions, especially with antiplatelet agents.
• Monitor magnesium levels: long‑term therapy can lead to hypomagnesemia.
• Evaluate bone health: prolonged use may affect calcium absorption.
• Use cautiously in pregnancy: weigh maternal benefit against potential fetal risk.

Store at ambient temperature: keep below 25 °C, protect from moisture and retain in original packaging.

Pantoprazole can affect the pharmacokinetics of several co‑administered medicines. Awareness of the interaction potential helps optimise therapy.

Major Interactions (Avoid)

• Clopidogrel: reduced antiplatelet effect, increasing cardiovascular event risk.
• Atazanavir and other protease inhibitors: markedly decreased absorption, compromising antiviral efficacy.

Moderate Interactions (Monitor Closely)

• Warfarin: possible increase in INR, requiring more frequent coagulation monitoring.
• Methotrexate: reduced renal clearance may raise serum levels, especially in high‑dose regimens.
• Digoxin: slight increase in serum concentration; monitor for toxicity signs.
• Oral contraceptives: modest reduction in hormone levels; advise backup contraception.